Cancer Chemotherapy I: Hepatocellular Injury

Clinics in Liver Disease

Volumn 11, Issue 3, 2007, Pages 641-662

  Rodriguez Frias, Edmundo A ^a   Lee, William M ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BILIRUBIN; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CLOFARABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUDARABINE; FLUOROURACIL; IRINOTECAN; MELPHALAN; MITOMYCIN C; MITOXANTRONE; PENTOSTATIN; PLANT EXTRACT; PROCARBAZINE; STREPTOZOCIN; THYMOCYTE ANTIBODY; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHORRHIZA EXTRACT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CHOLESTASIS; CLINICAL FEATURE; COLORECTAL CANCER; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FATTY LIVER; GRANULOMATOUS HEPATITIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FATTY DEGENERATION; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER INJURY; LIVER METABOLISM; LIVER METASTASIS; LIVER NECROSIS; LIVER TOXICITY; MELANOMA; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; REVIEW; SIDE EFFECT; SMALL CELL CARCINOMA; VEIN OCCLUSION; XANTHORRHIZA;

ANTINEOPLASTIC AGENTS; HEPATITIS, TOXIC; HUMANS;

EID: 34548116583     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.06.007     Document Type: Review

References (176)

1. McDonald G.B., and Tirumali N. Intestinal and liver toxicity of antineoplastic drugs. West J Med 140 (1984) 250-259
2. Lee W.M. Drug-induced hepatotoxicity. N Engl J Med 333 (1995) 1118-1127
3. Navarro V.J., and Senior J.R. Drug-related hepatotoxicity. N Engl J Med 354 (2006) 731-739
4. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 38 2 (2004) S44-S48
5. Riddick D.S., Lee C., Ramji S., et al. Cancer chemotherapy and drug metabolism. Drug Metab Dispos 33 8 (2005) 1083-1096
6. King P.D., and Perry M.C. Hepatotoxicity of chemotherapy and oncologic agents. Gastroenterol Clin North Am 24 4 (1995) 969-990
7. Strickland R.C., and Schenker S. The nephrogenic hepatic dysfunction syndrome: a review. Dig Dis 22 (1977) 49-55
8. Hoofnagle J.H., Dusheiko G.M., Schafer D.F., et al. Reactivation of chronic hepatitis B virus infection after discontinuation of low dose methotrexate therapy. Ann Intern Med 112 (1990) 381-382
9. Thung S.N., Gerber M.A., Klion F., et al. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 145 (1985) 1313-1314
10. Sturgill M., and Lambert G. Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. Clin Chem 43 8 (1997) 1512-1526
11. Pohl L.R. Drug-induced allergic hepatitis. Semin Liver Dis 10 (1990) 305-315
12. Fromenty B., and Pessayre D. Inhibition of mitochondrial beta-oxidase as a mechanism of hepatotoxicity. Pharmacol Ther 67 (1995) 101-154
13. McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118 (1993) 255-267
14. Shulman H.M., McDonald G.B., Matthews D., et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 79 (1980) 1178-1191
15. Edmondson H.A., Henderson B., and Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 294 (1976) 470-472
16. Gordon S.C., Reddy K.R., Livingstone A.S., et al. Resolution of a contraceptive-steroid induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 105 (1986) 547-549
17. McIntosh S., Davidson D.L., O'Brien R.T., et al. Methotrexate hepatotoxicity in children with leukemia. J Pediatr 90 (1977) 1019-1021
18. Grismer L.E., Gill S.A., and Harris M.D. Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. J Clin Rheumatol 7 4 (2001) 224-227
19. Aubrey D.A. Massive hepatic necrosis after cyclophosphamide. Br Med J 3 (1970) 588
20. Snyder L.S., Heigh R.L., and Anderson M.L. Cyclophosphamide induced hepatotoxicity in a patient with Wegener's granulomatosis. Mayo Clin Proc 68 (1993) 1203-1204
21. DeLeve L.D. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 24 (1996) 830-837
22. Koren G., Beatty K., Seto A., et al. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 26 3 (1992) 363-371
23. Hassan M., Ljungman P., Ringden O., et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 25 (2000) 915-924
24. Nevill T.J., Barnett M.J., Klingemann H.G., et al. Regimen-related toxicity of a busulphan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 9 (1991) 1224-1232
25. McDonald G.B., Slattery J.T., Bouvier M.E., et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101 5 (2003) 2043-2048
26. Shaunak S., Munro J.M., Weinbre K., et al. Cyclophosphamide induced liver necrosis: a possible interaction with azathioprine. Q J Med 252 (1988) 309-317
27. Kresse M., Latta M., Kunstle G., et al. Kupffer cell-expressed membrane-bound TNF mediates melphalan hepatotoxicity via activation of both TNF receptors. J Immunol 175 (2005) 4076-4083
28. Alexander H.R., Bartlett D.L., Libutti S.K., et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16 (1998) 1479-1489
29. Leff R.S., Thompson J.M., Johnson D.B., et al. Phase II trial of high dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma. J Clin Oncol 4 (1986) 1586-1591
30. Noter S.L., Rothbarth J., Pijl M.E., et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 14 (2004) 67-72
31. Rothbarth J., Woutersen R.A., Sparidans R.W., et al. Melphalan antitumor efficacy and hepatotoxicity: the effect of variable infusion duration in the hepatic artery. J Pharmacol Exp Ther 305 3 (2003) 1098-1103
32. Amromin G.D., Delman R.M., and Shanbran E. Liver damage after chemotherapy for leukemia and lymphoma. Gastroenterology 42 (1962) 401-410
33. Koler R.D., and Forsgren A.L. Hepatotoxicity due to chlorambucil. Report of a case. JAMA 167 (1958) 316-317
34. McMaster K., and Hennigar G. Drug-induced granulomatous hepatitis. Lab Invest 44 (1981) 61-73
35. Meredith M.J., and Reed D.J. Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by Adriamycin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol 32 8 (1983) 1383-1388
36. Phillips G., Fay J., Herzig G., et al. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer 52 10 (1983) 1792-1802
37. Kristal H., Rassnick K., et al. Hepatotoxicity associated with CCNU (Lomustine) chemotherapy in dogs. J Vet Intern Med 18 (2004) 75-80
38. Wang T., Fontenot R.D., Soni M.G., et al. Enhanced hepatotoxicity and toxic outcome of thioacetamide in streptozotocin-induced diabetic rats. Toxicol Appl Pharmacol 166 2 (2000) 92-100
39. Broder L.E., and Carter S.K. Pancreatic islet cell carcinoma II: results of therapy with streptozotocin in 52 patients. Ann Intern Med 79 (1973) 108-118
40. Schein P.S., O'Connell M.J., Blom J., et al. Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 34 (1974) 993-1000
41. Liu J., Liu Y., Habeebu S., et al. Metallothionein null mice are sensitive to cisplatin-induced hepatotoxicity. Toxicol Appl Pharmacol 149 (1998) 24-31
42. Cersosimo R.J. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother 27 (1993) 438-441
43. Pollera C.F., Ameglio F., Nardi M., et al. Cisplatin-induced hepatic toxicity. J Clin Oncol 5 (1987) 318-319
44. Kim S.H., Hong K.O., Chung W.Y., et al. Abrogation of cisplatin-induced hepatotoxicity in mice by xanthorrhizol is related to its effect on the regulation of gene transcription. Toxicol Appl Pharmacol 196 (2004) 346-355
45. Hong K.O., Hwang J.K., Park K.K., et al. Phosphorylation of c-Jun N-terminal Kinases (JNKs) is involved in the preventive effect of xanthorrhizol on cisplatin-induced hepatotoxicity. Arch Toxicol 79 (2005) 231-236
46. Kobayashi K., and Tsukamoto I. Prolonged Jun N-terminal (JNK) activation and the upregulation of p53 and p21 preceded apoptosis in hepatocytes after partial hepatectomy and cisplatin. Biochim Biophys Acta 1537 (2001) 79-88
47. Rossi A., Maione P., and Gridelli C. Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients. Expert Opin Drug Saf 4 6 (2005) 1051-1067
48. Hruban R., Sternberg S.S., Meyers P., et al. Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest 9 (1991) 263-268
49. Seong J., Han K.H., Park Y.N., et al. Lethal hepatic injury by combined treatment of radiation plus chemotherapy in rats with thioacetamide-induced liver cirrhosis. Int J Radiat Oncol Biol Phys 57 1 (2003) 282-288
50. Matsumoto M., Nakao K., Matsumoto H., et al. Chronic liver failure induced by long-term administration of tegafur: a case report. Hepatogastroenterology 45 24 (1998) 2372-2375
51. Fakih M.G. 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction. Oncology 67 3-4 (2004) 222-224
52. Mori T., Munakata M., Kasai M., et al. Successful treatment of 5-FU intraarterial infusion on the third postoperative day for a patient with multiple liver metastases from colon cancer and high risk of liver failure. Gan To Kagaku Ryoho 31 7 (2004) 1101-1103
53. Chang A.E., Schneider P.D., Sugarbaker P.H., et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206 6 (1987) 685-693
54. Hohn D., Melnick J., Stagg R., et al. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 32 (1985) 161-169
55. Doria M.I., Shepard K.V., Levin B., et al. Liver pathology following hepatic arterial infusion chemotherapy: hepatic toxicity with FUDR. Cancer 58 (1986) 855-861
56. Sullivan R.D., Norcross J.W., and Watkins Jr. E. Chemotherapy by prolonged hepatic-artery infusion. N Engl J Med 270 (1964) 321-327
57. Niederhuber J.E., and Grochow L.B. Status of infusion chemotherapy for the treatment of liver metastases. Princ Pract Oncol Updates 3 (1989) 1-9
58. Kavana G.H., Krakoff I.H., Bodey G., et al. Phase I study of fludarabine. Eur J Cancer Clin Oncol 21 (1985) 1009-1011
59. Kroger N., Schetelig J., and Zabelina T.A. Fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 28 7 (2001) 643-647
60. Uy G.L., Tomasson M.H., Ruddell A., et al. The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma. Haematologica 91 (2006) 1581-1582
61. Gandhi V., Plunkett W., Bonate P.L., et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res 12 (2006) 4011-4017
62. Ho A.D., Suciu S., Stryckmans P., et al. Pentostatin in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer. Semin Oncol 27 2 (2000) 52-57
63. Johnson S.A., Catovsky D., Child J.A., et al. Phase I/II evaluation of Pentostatin in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Invest New Drugs 16 2 (1998) 155-160
64. Poplack D.G., Sallan S.E., Rivera G., et al. Phase I study of 2′-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res 41 (1981) 3343-3346
65. Reed D.J., and Frariss M.W. Glutathione depletion and susceptibility. Pharmacol Rev 36 (1984) 25-33
66. Llesuy S.F., and Arnaiz S.L. Hepatotoxicity of mitoxantrone and doxorubicin. Toxicology 63 2 (1990) 187-198
67. Kalender Y., Yel M., and Kalender S. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology 209 1 (2005) 39-45
68. Wang L., and Lin S. Protective and antioxidative effect of 2(3)tert-butyl-4-hydroxyanisole against cytotoxicity induced by doxorubicin in mice. Yao Xue Xue Bao 33 11 (1998) 807-811
69. Kimura T., Fujita I., Itoh N., et al. Metallothionein acts as a cytoprotectant against doxorubicin toxicity. J Pharmacol Exp Ther 292 1 (2000) 299-302
70. Kwiecien I., Michalska M., and Wlodek L. The selective effect of cystathionine on doxorubicin hepatotoxicity in tumor-bearing mice. Eur J Pharmacol 550 1-3 (2006) 39-46
71. Oz E., and Ilhan M.N. Effects of melatonin in reducing the toxic effects of doxorubicin. Mol Cell Biochem 286 1-2 (2006) 11-15
72. Yeo W., Mok T.S., Tse K.K., et al. Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer. Anticancer Drugs 13 6 (2002) 655-662
73. Twelves C.J., Dobbs N.A., Gillies H.C., et al. Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests. Cancer Chemother Pharmacol 42 (1998) 229-234
74. Twelves C.J., Dobbs N.A., Michael Y., et al. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer 66 (1992) 765-769
75. Brenner D.E., Wiernik P.H., Wesley M., et al. Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer 53 (1984) 1042-1048
76. Blum R.H., Carter S.K., and Agre K. A clinical review of bleomycin. A new antineoplastic agent. Cancer 31 (1973) 903-914
77. Floyd J., Mirza I., Sachs B., et al. Hepatotoxicity of chemotherapy. Semin Oncol 33 (2006) 50-67
78. Newman R.A., Siddik Z.H., Travis E.L., et al. Assessment of pulmonary and hematologic toxicities of liblomycin, a novel bleomycin analog. Invest New Drugs 8 1 (1990) 33-41
79. Kemeny N., Eid A., Stockman J., et al. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol 91 2 (2005) 97-101
80. Marinelli A., de Brauw L.M., Beerman H., et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 26 5 (1996) 341-350
81. Canal P., Chatelut E., and Guichard S. Practical treatment guide for dose individualization in cancer chemotherapy. Drugs 56 6 (1998) 1019-1038
82. Joel S.P., Hall M., Gaver R.C., et al. Complete recovery of radioactivity after administration of 14C-etoposide in man. [abstract]. Annu Meet Am Soc Clin Oncol 14 (1995) 168
83. Wolff S.N., Johnson D.H., Greco F.A., et al. Etoposide induced hepatic injury: a potential complication of high-dose therapy. Cancer Treat Rep 67 (1983) 1023-1024
84. Stewart C.F., Pieper J.A., Arbuck S.G., et al. Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther 45 (1989) 49-55
85. Arbuck S.G., Douglas H.O., Crom W.R., et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 4 (1986) 1690-1695
86. Slichenmyer W.J., Rowinsky E.K., Grochow L.B., et al. Camptothecin analogues: studies from the Johns Hopkins Oncology Center. Cancer Chemother Pharmacol 34 (1994) S53-S57
87. O'Reilly S., Rowinsky E., Slichenmyer W., et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 88 (1996) 817-824
88. King P.D., and Perry M.C. Hepatotoxicity of chemotherapy. Oncologist 6 (2001) 162-176
89. Burris H.A., and Fields F.M. Topoisomerase inhibitors. Hematol Oncol Clin Norht Am 8 (1994) 333-355
90. Siu L.L., and Rowinsky E.K. A risk benefit assessment of irinotecan in solid tumors. Drug Saf 4 (1998) 783-789
91. Kearns C., Gianni L., and Egorin M. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22 (1995) 16-23
92. Sonnichsen D.S., and Relling M.V. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27 (1994) 256-269
93. Sonnichsen D.S., Liu Q., Schuetz E.G., et al. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275 (1995) 566-575
94. Jiko M., Yano I., Okuda M., et al. Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure. Pharm Res 22 2 (2005) 228-234
95. Choi J.S. Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure. Arch Pharm Res 25 6 (2002) 973-977
96. Venook A.P., Egorin M.J., Rosner G.L., et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 16 (1998) 1811-1819
97. Oettle H., Arnold D., Esser M., et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11 8 (2000) 635-638
98. Huizing M.T., Rosing H., and Vermoken J. Pharmacology of paclitaxel and its metabolites in patients with altered liver function. Eur J Cancer 31A 5 (1995) S192
99. Panday V.R., Huizing M.T., Willense P.H., et al. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 24 11 (1997) 34-38
100. Bruno R., and Sanderink G.J. Pharmacokinetics and metabolism of docetaxel. Cancer Surv 17 (1993) 305-313
101. Alexandre J., Bleuzen P., Bonneterre J., et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pre-treated advanced breast cancer patients. J Clin Oncol 18 (2000) 562-573
102. Bruno R., Hill D., Riva A., et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16 (1998) 187-196
103. Rahmani R., and Zhou X.J. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 17 (1993) 269-281
104. El Saghir N.S., and Hawkins K.A. Hepatotoxicity following vincristine therapy. Cancer 54 (1984) 2006-2008
105. Desai Z.R., Van Den Berg H., Bridges J.M., et al. Can severe vincristine neurotoxicity be prevented?. Cancer Chemother Pharmacol 8 (1982) 211-214
106. Van Den Berg H., Desai Z.R., Wilson R., et al. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 8 (1982) 215-219
107. Blay J.Y., Le Cesne A., Verweij J., et al. A phase II study of ET-743/trabectedin for patients with advanced gastrointestinal stromal tumors. Eur J Cancer 40 9 (2004) 1327-1331
108. Garcia-Carbonero R., Supko J.G., Manola J., et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22 8 (2004) 1480-1490
109. Beumer J.H., Schellens J.H.M., and Beijnen J.H. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacol Res 51 (2005) 391-398
110. Van Kesteren C., de Vooght M.M., Lopez-Lazaro L., et al. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs 14 7 (2003) 487-502
111. Grosso F., Dileo P., Sanfilippo R., et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 42 10 (2006) 1484-1490
112. Donald S., Verschoyle R.D., Greaves P., et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat. Cancer Res 63 18 (2003) 5902-5908
113. Fenton C., and Perry C. Gemtuzumab ozogamicin. A review of its use in acute myeloid leukemia. Drugs 65 16 (2005) 2406-2427
114. Larson R.A., Sievers E.L., Stadmauer E.A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104 7 (2005) 1442-1452
115. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 1001;7:1490-6
116. Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leucemia. Cancer Chemother Pharmacol 220;51:87-90
117. Fenton C., and Perry C. Spotlight on gemtuzumab ozogamicin in acute myeloid leukemia. Biodrugs 20 2 (2006) 137-139
118. Ransom M., and Wardell S. Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther 29 2 (2004) 95-103
119. Yoshimoto A., Kasahara K., Kimura H., et al. Transient liver injury caused by gefitinib. Nihon Kokyuki Gakkai Zasshi 42 1 (2004) 56-61
120. Niho S., Kubota K., Goto K., et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 24 1 (2006) 64-69
121. Seki N., Uematsu K., Shibakuki R., et al. Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J Clin Oncol 19 1 (2006) 3213-3214
122. Ramanarayanan J., and Scarpace S.L. Acute drug induced hepatitis due to erlotinib. JOP 8 1 (2007) 39-43
123. Kikuchi S., Muroi K., Takahashi S., et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its concentration with clinical outcomes. Leuk Lymphoma 45 (2004) 2349-2351
124. Ohyashiki K., Kuriyama Y., Nakajima A., et al. Imatinib mesylate induced hepatotoxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 16 (2004) 2160-2161
125. Johnson J.R., Bross P., Cohen M., et al. Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 9 (2003) 1972-1979
126. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
127. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 23 (2006) 2408-2417
128. Cohen M.H., Williams G., Johnson J.R., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8 (2002) 935-942
129. Cross T.J., Bagot C., Portmann B., et al. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 81 3 (2006) 189-192
130. Lin N.U., Sarantopoulos S., Stone J.R., et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood 102 (2003) 3455-3456
131. Ayoub W.S., Geller S.A., Tran T., et al. Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol 39 (2005) 75-77
132. Guilhot F. Indications for imatinib mesylate therapy and clinical management. The Oncologist 9 (2004) 271-281
133. Mindikoglu A.L., Regev A., Bejarano P.A., et al. Imatinib mesylate (Gleevec) hepatotoxicity. Dig Dis Sci 52 (2007) 598-601
134. Dhalluin-Venier V., Besson C., Dimet S., et al. Imatinib mesylate-induced acute hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 18 11 (2006) 1235-1237
135. Ikuta K., Torimoto Y., Jimbo J., et al. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. Int J Hematol 82 4 (2005) 343-346
136. Ferrero D., Pogliani E.M., Rege-Cambrin G., et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haemotologica 91 (2006) 35-37
137. Buzdar A., Howell A.Z.Z., Cuzick J., et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
138. de la Cruz L., Romero-Vasquez J., Jimenez-Saenz M., et al. Severe acute hepatitis in a patient treated with anastrozole. Lancet 369 (2007) 23-24
139. Zapata E., Zubiaurre L., Bujanda L., et al. Anastrozole-induced hepatotoxicity. Eur J Gastroenterol Hepatol 18 (2006) 1233-1234
140. Hillner B.E. Anastrozole had a better risk-benefit profile than tamoxifen as adjuvant treatment for breast cancer in postmenopausal women. ACP J Club 146 1 (2007) 4
141. Polychronis A., Sinnett H.D., Hadjiminas D., et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6 (2005) 383-391
142. Carlini P., Papaldo P., Fabi A., et al. Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?. J Clin Oncol 24 35 (2006) e60-e61
143. Cetin M., Demirci D., Unal A., et al. Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. Hum Exp Toxicol 18 (1999) 137-140
144. Lubbert C., Wiese M., Haupt R., et al. Toxic hepatitis and liver failure under therapy with flutamide. Internist 45 3 (2004) 333-340
145. Crownover R.L., Holland J., Chen A., et al. Flutamide-induced liver toxicity including fatal hepatic necrosis. Int J Radiat Oncol Biol Phys 34 4 (1996) 911-915
146. Okaneya T., Murata Y., and Kinebuchi Y. Fatal hepatic failure following hepatitis caused by flutamide: a case report. Nippon Hinyokika Gakkai Zasshi 90 5 (1999) 590-593
147. Dourakis S.P., Alexopoulou A.A., and Hadziyannis S.J. Fulminant hepatitis after flutamide treatment. J Hepatol 20 3 (1994) 350-353
148. Garcia Cortes M., Andrade R.J., Lucena M.I., et al. Flutamide-induced hepatotoxicity: report of a case series. Rev Esp Enferm Dig 93 7 (2001) 423-432
149. Andrejak M., Nguyen-Khac E., Decocq G., et al. Fulminant hepatitis caused by flutamide. Gastroenterol Clin Biol 20 1 (1996) 121-122
150. Wysowski D.K., Freiman J.P., Tourtelot J.B., et al. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 118 11 (1993) 860-864
151. Fernandez Pena C.M., Morano L.E., Montes S.J., et al. Fulminant liver failure with a fatal outcome due to flutamide. Med Clin (Barc) 108 6 (1997) 237-238
152. Lee H.W., Chung J.P., Lee K.S., et al. A case of flutamide-induced acute cholestatic hepatitis. Yonsei Med J 37 3 (1996) 225-229
153. Wysowski D.K., and Fourcroy J.L. Flutamide and hepatotoxicity. J Urol 155 (1996) 209-212
154. Lin A.D., Chen K.K., Lin A.T., et al. Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer. J Chin Med Assoc 66 12 (2003) 735-740
155. Manso G., Thole Z., Salqueiro E., et al. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol Drug Saf 15 4 (2006) 253-259
156. Boelsterli U.A., Ho H.K., Zhou S., et al. Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab 7 7 (2006) 715-727
157. Legro R.S. Long-term, low-dose flutamide does not cause hepatotoxicity in hyperandrogenic women. Nat Clin Pract Endocrinol Metab 2 4 (2006) 188-189
158. Ibanez L., Jaramillo A., Ferrer A., et al. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod 20 7 (2005) 1833-1836
159. Kojima M., Kamoi K., Ukimura O., et al. Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: a preliminary study. Int J Urol 9 1 (2002) 42-46
160. Cicognani C., Malavolti M., Morselli-Labate A.M., et al. Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. Dig Dis Sci 41 11 (1996) 2219-2221
161. Velcade (bortezomib) [package insert]. Cambridge (MA): Millenium Pharmaceuticals; 2003
162. Schwartz R., and Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology 18 14 (2004) 14-21
163. San Miguel J., and Blade J. Perspective on the current use of bortezomib in multiple myeloma. Haematologica 91 7 (2006) 871-872
164. Rosinol L., Montoto S., Cibeira M.T., et al. Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Arch Intern Med 165 (2005) 464-465
165. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
166. Steins M.B., Padro T., Bieker R., et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 99 (2002) 834-839
167. Dimopoulos M., and Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117 7 (2004) 508-515
168. Offidani M., Corvatta L., Marconi M., et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 72 6 (2004) 403-409
169. Fowler R., and Imrie K. Thalidomide-associated hepatitis: a case report. Am J Hematol 66 (2001) 300-302
170. Trojan A., Chasse E., Gay B., et al. Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma. Ann Oncol 14 (2003) 501-502
171. Fishman A.D., and Wadler S. Advances in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer 1 1 (2001) 20-35
172. Feliu J., Mel J.R., Camps C., et al. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer an active and low toxicity regimen. Eur J Cancer 38 9 (2002) 1204-1211
173. Romiti A., Tonini G., Santini G., et al. Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer. Anticancer Res 22 5 (2002) 3071-3076
174. Raderer M., Fiebiger W., Wrba F., et al. Fatal liver failure after the administration of raltitrexed for cancer chemotherapy: a report of two cases. Cancer 89 4 (2000) 890-892
175. Flamenbaum M., Kemeny J.L., Garcia V., et al. Non-alcoholic steatohepatitis with cirrhosis after raltitrexed administration. Gastroenterol Clin Biol 25 2 (2001) 200-201
176. Massacesi C., Sanitin D., Rocchi M.B., et al. Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. Anti Cancer Drugs 14 7 (2003) 533-541